Form 8-K - Current report:
SEC Accession No. 0001104659-23-081202
Filing Date
2023-07-14
Accepted
2023-07-14 16:05:20
Documents
12
Period of Report
2023-07-10
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2321301d1_8k.htm   iXBRL 8-K 28162
  Complete submission text file 0001104659-23-081202.txt   202066

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20230710.xsd EX-101.SCH 3021
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20230710_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20230710_pre.xml EX-101.PRE 22363
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2321301d1_8k_htm.xml XML 3311
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 231089160
SIC: 2834 Pharmaceutical Preparations